key: cord-0781073-9v1lfd0r
authors: Levraut, Michael; Ottavi, Marie; Lechtman, Sarah; Mondain, Véronique; Jeandel, Pierre‐Yves
title: Immune thrombocytopenic purpura after COVID‐19 infection
date: 2020-09-20
journal: Int J Lab Hematol
DOI: 10.1111/ijlh.13346
sha: 4ce7f3f82fdd560fff7773d998bf923e69b367d2
doc_id: 781073
cord_uid: 9v1lfd0r

nan

Dear Editor,

The novel coronavirus disease 2019 (COVID-19) occurring in many countries worldwide has shown to be associated with hematological disorders. 1, 2 Moderate thrombocytopenia has been found in nearly 36% of COVID-19 patients. 2 However, deep thrombocytopenia is rare and is associated with disease severity. 3 Thrombocytopenia pathogenesis during COVID-19 seems to be complex and multifactorial. 4, 5 Immuno-hematological diseases have been described in patients with COVID-19, such as immune thrombocytopenic purpura (ITP), 6, 7 autoimmune hemolytic anemia (AIHA), 8 and antiphospholipid syndrome. 9 Here, we wish to report a case of new-onset ITP occurring a month after first COVID-19 symptoms.

A 63-year-old woman with autoimmune hypothyroidism and stroke medical history presented to the emergency department for a 7-day history of asthenia, fever, dry cough, and headaches. At admission, she was afebrile and her vitals were unremarkable. She was able to breathe normally without oxygen. Chest examination found bilateral crackles of lung bases. Blood tests showed lymphocytopenia (600/mm 3 ), with normal platelets (197 000/mm 3 ) and hemoglobin (12.4 g/dL) levels. C-reactive protein (CRP) was 38 mg/L, and creatinine was in the normal range. She was tested negative for the nasal SARS-CoV-2 real-time reverse transcriptase-polymerase chain reaction (RT-PCR) but her chest CT scan found bilateral and subpleural frosted glass beaches, predominant in the two lower lung lobes (10% to 25% of all lung volume), evocative of moderate COVID-19 pneumonia ( Figure 1A ). Her husband was tested positive for the nasal SARS-CoV-2 RT-PCR the same day. Because of normal vital parameters, she was able to go back home. She started a self-medication with azithromycin 500 mg per day and hydroxychloroquine 600 mg per day for 6 and 12 days, respectively.

On day 26 after first symptoms, she presented again to the emergency department because of a lower limb purpura ( Figure 1B) . She was afebrile, without cough and headaches since a week. She did not report digestive bleeding nor hematuria. Physical examination found bruises of both arms and legs, and there was no neurologic abnormality. Laboratory tests found severe thrombocytopenia (3000/ cannot be confirmed in our patient, these observations support that a close follow-up after COVID-19 is needed for such patients.

Moreover, drug-induced ITP has also been reported. While hydroxychloroquine-induced thrombocytopenia has never been reported, macrolide-induced severe thrombocytopenia has been described including azithromycin. 13 This exceptional drug-induced side effect always appears during the course of azithromycin treatment. In our observation, ITP diagnosis has been made 13 days after drug discontinuation. Therefore, it did not support drug-induced thrombocytopenia.

Therapeutic management of ITP during COVID-19 pandemic is difficult, and patricians need to consider bleeding, thrombotic and septic risks of each patient to lead ITP treatment. 5 However, IvIg permitted to quickly increase platelet counts in our patient, without side effect. In the case series of Mahevas et al, 7 IvIg was used in 9/14 cases and all patients completely recovered from ITP and COVID-19 without thrombotic complication. It suggests that IvIg can be used in such patients, without severe side effects. 

Hematologic parameters in patients with COVID-19 infection

Clinical characteristics of coronavirus disease 2019 in China

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis

Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge

Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic

Immune thrombocytopenic purpura in a patient With Covid-19

Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series

Autoimmune haemolytic anaemia associated with COVID-19 infection

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 Tests by time since exposure

Epidemiology of incident immune thrombocytopenia : a nationwide population-based study in France

Thrombocytopenia in patients with severe acute respiratory syndrome (review)

Azithromycin-induced thrombocytopenia: a rare etiology of drug-induced immune thrombocytopenia